
Presented additional preclinical data supporting IBIO-610's potential to drive fat selective weight loss in combination with GLP-1 therapy
iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | 100,000 |
| Gross Profit (TTM) | 100,000 |
| EBITDA | $-29.49M |
| Operating Margin | -30138.00% |
| Return on Equity | -65.70% |
| Return on Assets | -30.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.54 |
| Price-to-Book | 0.55 |
| Price-to-Sales (TTM) | 394.94 |
| EV/Revenue | 3.508 |
| EV/EBITDA | -1.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $64.31M |
| Float | $46.11M |
| % Insiders | 1.32% |
| % Institutions | 64.97% |
Volatility is currently expanding

Presented additional preclinical data supporting IBIO-610's potential to drive fat selective weight loss in combination with GLP-1 therapy

SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the following investor conferences in November and December 2026.

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate, alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity. The data were discussed in an oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026.

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,” said Martin Brenner, Ph.D.

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development.

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference.

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition

Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporate update on its progress. “This last quarter was marked by significant advancement across our full pipeline.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IBIO and any ticker you trade — then tracks every position and per-strategy win rate.